Unknown

Dataset Information

0

Clinical Grade Production of Wilms' Tumor-1 Loaded Cord Blood-Derived Dendritic Cells to Prevent Relapse in Pediatric AML After Cord Blood Transplantation.


ABSTRACT: Hematopoietic cell transplantation (HCT) is a last resort, potentially curative treatment option for pediatric patients with refractory acute myeloid leukemia (AML). Cord blood transplantation (CBT) results in less relapses and less graft-versus-host disease when compared to other sources. Nevertheless, still more than half of the children die from relapses. We therefore designed a strategy to prevent relapses by inducing anti-AML immunity after CBT, using a CB-derived dendritic cell (CBDC) vaccine generated from CD34+ CB cells from the same graft. We here describe the optimization and validation of good manufacturing practice (GMP)-grade production of the CBDC vaccine. We show the feasibility of expanding low amounts of CD34+ cells in a closed bag system to sufficient DCs per patient for at least three rounds of vaccinations. The CBDCs showed upregulated costimulatory molecules after maturation and showed enhanced CCR7-dependent migration toward CCL19 in a trans-well migrations assay. CBDCs expressed Wilms' tumor 1 (WT1) protein after electroporation with WT1-mRNA, but were not as potent as CBDCs loaded with synthetic long peptides (peptivator). The WT1-peptivator loaded CBDCs were able to stimulate T-cells both in a mixed lymphocyte reaction as well as in an antigen-specific (autologous) setting. The autologous stimulated T-cells lysed not only the WT1+ cell line, but most importantly, also primary pediatric AML cells. Altogether, we provide a GMP-protocol of a highly mature CBDC vaccine, loaded with WT1 peptivator and able to stimulate autologous T-cells in an antigen-specific manner. Finally, these T-cells lysed primary pediatric AML demonstrating the competence of the CBDC vaccine strategy.

SUBMITTER: Plantinga M 

PROVIDER: S-EPMC7546401 | biostudies-literature | 2020

REPOSITORIES: biostudies-literature

altmetric image

Publications

Clinical Grade Production of Wilms' Tumor-1 Loaded Cord Blood-Derived Dendritic Cells to Prevent Relapse in Pediatric AML After Cord Blood Transplantation.

Plantinga Maud M   Lo Presti Vania V   de Haar Colin G CG   Dünnebach Ester E   Madrigal Alejandro A   Lindemans Caroline A CA   Boelens Jaap Jan JJ   Nierkens Stefan S  

Frontiers in immunology 20200925


Hematopoietic cell transplantation (HCT) is a last resort, potentially curative treatment option for pediatric patients with refractory acute myeloid leukemia (AML). Cord blood transplantation (CBT) results in less relapses and less graft-versus-host disease when compared to other sources. Nevertheless, still more than half of the children die from relapses. We therefore designed a strategy to prevent relapses by inducing anti-AML immunity after CBT, using a CB-derived dendritic cell (CBDC) vacc  ...[more]

Similar Datasets

| S-EPMC4589057 | biostudies-literature
| S-EPMC5830127 | biostudies-literature
| S-EPMC6627518 | biostudies-literature
| S-EPMC6963241 | biostudies-literature
| S-EPMC8119290 | biostudies-literature
| S-EPMC2774557 | biostudies-literature
| S-EPMC6142604 | biostudies-literature
| S-EPMC9152997 | biostudies-literature
| S-EPMC7499897 | biostudies-literature
| S-EPMC6076982 | biostudies-literature